SCHEMBL3565154

SCHEMBL3565154

Cc1cc(NC(=O)NCCN2CCC(N(C3CC3)S(=O)(=O)c3ccccc3)CC2)cc(C)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 4/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
POLB P06746 2/20 0.45
ADRA2A P08913 1/20 0.44
DRD2 P14416 1/20 0.44
SLC6A2 P23975 1/20 0.44
HTR2A P28223 1/20 0.44
HTR2C P28335 1/20 0.44
SLC6A4 P31645 1/20 0.44
TMEM97 Q5BJF2 1/20 0.44
SIGMAR1 Q99720 1/20 0.44
MAPT P10636 1/20 0.44
CA1 P00915 3/20 0.43
CA2 P00918 3/20 0.43
CA7 P43166 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
RAB9A P51151 1/20 0.42
TP53 P04637 1/20 0.42
CCR3 P51677 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3562248 0.93 CA2 (0.48) UTS2RMEN1KMT2AADRA2ADRD2
SCHEMBL3556333 0.92 HTR2A (0.43) UTS2RMEN1KMT2APOLBADRA2A
SCHEMBL3564369 0.91 CNR1 (0.48) POLBMAPTCA1CA2TP53
SCHEMBL3561058 0.91 CCR3 (0.47) MEN1KMT2AHTR2ACA1CA2
SCHEMBL3565549 0.91 HTR2A (0.49) UTS2RMEN1KMT2APOLBADRA2A
SCHEMBL3554219 0.90 CCR3 (0.45) UTS2RDRD2HTR2AHTR2CCA1
SCHEMBL3562875 0.90 MAPT (0.46) UTS2RMEN1KMT2AHTR2AHTR2C
SCHEMBL3935211 0.90 L3MBTL1 (0.48) POLBCA1CA2CA7CCR3
SCHEMBL3562731 0.90 POLB (0.45) UTS2RMEN1KMT2APOLBADRA2A
SCHEMBL3564763 0.90 NAMPT (0.47) UTS2RMEN1KMT2APOLBADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7750161-B2 Pyridine derivatives ACTELION PHARMACEUTICALS, LTD. (CH) 2010-07-06 US claimed
EP-1670470-B1 PYRIDINE DERIVATIVES AND USE THEREOF AS UROTENSIN II ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2009-04-08 EP claimed
US-20070043081-A1 Novel pyridine derivatives ACTELION PHARMACEUTICALS, LTD. (CH) 2007-02-22 US claimed
US-7750161-B2 Pyridine derivatives ACTELION PHARMACEUTICALS, LTD. (CH) 2010-07-06 US disclosed
EP-1670470-B1 PYRIDINE DERIVATIVES AND USE THEREOF AS UROTENSIN II ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2009-04-08 EP disclosed
US-20070043081-A1 Novel pyridine derivatives ACTELION PHARMACEUTICALS, LTD. (CH) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043081-A1 Novel pyridine derivatives P2RY4, P2RX6, P2RX4 UTS2R 636/4885MEN1 1845/4885KMT2A 3265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.